Jul 21, 2026 04:06PM

Jul 21, 2026 04:05PM

Mar 6, 2026 07:45AM

Jan 7, 2026 04:06PM

Jan 7, 2026 04:00PM

Dec 17, 2025 04:05PM

Dec 17, 2025 04:05PM Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Dec 12, 2025 10:47AM

Nov 19, 2025 09:45AM

Sep 16, 2025 07:00AM

Sep 16, 2025 07:00AM

Aug 13, 2025 04:05PM

Jul 9, 2025 08:00AM

Mar 20, 2025 04:05PM Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Jan 7, 2025 07:04AM

Jan 7, 2025 07:00AM

Dec 17, 2024 08:00AM

Dec 12, 2024 08:00AM

Dec 12, 2024 08:00AM

Nov 13, 2024 04:05PM

Oct 15, 2024 08:01AM Immuneering Corporation (IMRX) Granted Orphan Drug Designation for IMM-1-104

Oct 15, 2024 08:00AM

Oct 15, 2024 08:00AM

Sep 12, 2024 04:06PM

Sep 12, 2024 04:05PM

Aug 6, 2024 04:05PM

Jul 31, 2024 04:05PM

May 7, 2024 04:05PM Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Mar 6, 2024 08:00AM

Mar 1, 2024 08:00AM

Feb 20, 2024 08:00AM

Feb 20, 2024 08:00AM

Dec 12, 2023 08:00AM

Dec 12, 2023 08:00AM

Mar 6, 2023 04:05PM Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Mar 6, 2023 04:05PM

Sep 30, 2022 06:52AM

Sep 30, 2022 06:50AM

Sep 30, 2022 06:50AM

Sep 2, 2022 08:09AM

Sep 2, 2022 08:09AM

Sep 2, 2022 08:09AM Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Mar 31, 2022 04:05PM

Mar 10, 2022 06:34AM

Mar 10, 2022 06:30AM

Mar 10, 2022 06:30AM

Jan 18, 2022 06:50AM

Jan 18, 2022 06:50AM

Jan 18, 2022 06:50AM Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.

Jan 6, 2022 04:14PM

326,131 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All